Clinical trial reveals twice-yearly injection reduces risk of HIV infection by 96% Medical XpressGilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results Business WireTwice-Yearly Lenacapavir for PrEP Reduces HIV Infections by 96% | Newswise NewswiseGilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic CSRwire.comGilead's Scientific Innovation at the Forefront of Helping End the HIV Epidemic Gilead Sciences